November 7, 2012
Otsuka Pharmaceutical announced on November 5 that its vasopressin V 2 -receptor antagonist tolvaptan suppressed the rate of increase in total kidney volume by around 50% compared to placebo in a PIII clinical trial conducted in patients with autosomal dominant...read more